Berenberg Bank reissued their hold rating on shares of Hikma Pharmaceuticals (LON:HIK – Free Report) in a research report report published on Thursday morning, Marketbeat Ratings reports. Berenberg Bank currently has a GBX 2,000 ($24.70) target price on the stock.
Separately, Barclays restated an equal weight rating and set a GBX 2,000 ($24.70) target price on shares of Hikma Pharmaceuticals in a research report on Monday, April 8th. Three investment analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. According to data from MarketBeat, the stock has a consensus rating of Moderate Buy and an average target price of GBX 2,068.75 ($25.55).
View Our Latest Report on Hikma Pharmaceuticals
Hikma Pharmaceuticals Stock Up 3.2 %
Hikma Pharmaceuticals Increases Dividend
The firm also recently declared a dividend, which will be paid on Friday, May 3rd. Investors of record on Thursday, March 21st will be issued a $0.47 dividend. The ex-dividend date is Thursday, March 21st. This is a boost from Hikma Pharmaceuticals’s previous dividend of $0.25. This represents a yield of 1.86%. Hikma Pharmaceuticals’s payout ratio is currently 8,507.46%.
Hikma Pharmaceuticals Company Profile
Hikma Pharmaceuticals PLC develops, manufactures, markets, and sells a range of generic, branded, and in-licensed pharmaceutical products. It operates through three segments: Injectables, Generics, and Branded. The Injectables segment provides generic injectable products primarily for use in hospitals.
Read More
- Five stocks we like better than Hikma Pharmaceuticals
- What is MarketRank™? How to Use it
- Snap Crackles and Pops on Surprise Profit and Raised Guidance
- 3 Warren Buffett Stocks to Buy Now
- MarketBeat Week in Review – 4/22 – 4/26
- What Investors Need to Know About Upcoming IPOs
- 3 Stocks Leading the U.S. Agriculture Comeback
Receive News & Ratings for Hikma Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hikma Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.